AIG
TRVI icon

American International Group’s Trevi Therapeutics TRVI Stock Holding History

American International Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,773
Closed -$71.7K – 2520
2024
Q1 		$71.7K Sell
20,773
-178
-0.8% -$397 ﹤0.01% 2679
2023
Q4 		$28.1K Buy
20,951
+176
+0.8% +$266 ﹤0.01% 2923
2023
Q3 		$45.3K Buy
20,775
+738
+4% +$1.67K ﹤0.01% 2840
2023
Q2 		$47.9K Buy
+20,037
New +$50.5K ﹤0.01% 2895

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

American International Group's TRVI Position: Q2 2024 in Review

American International Group sold out of Trevi Therapeutics (TRVI) in Q2 2024, closing a stake of 20,773 shares — an estimated $71.7K sold.

American International Group first reported a position in TRVI in Q2 2023 and held it in 4 quarters. The position peaked at $71.7K in Q1 2024. 77 funds tracked by Wall St. Rank hold TRVI as of Q2 2024.

  • American International Group reported no remaining Trevi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 20,773 Trevi Therapeutics shares in Q2 2024, an estimated $71.7K.
  • American International Group first reported a position in Trevi Therapeutics in Q2 2023 and held it in 4 quarters.
  • American International Group's Trevi Therapeutics position peaked at $71.7K in Q1 2024.
  • 77 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.